» Articles » PMID: 33824489

Emerging Concepts in the Science of Vaccine Adjuvants

Overview
Specialty Pharmacology
Date 2021 Apr 7
PMID 33824489
Citations 466
Authors
Affiliations
Soon will be listed here.
Abstract

Adjuvants are vaccine components that enhance the magnitude, breadth and durability of the immune response. Following its introduction in the 1920s, alum remained the only adjuvant licensed for human use for the next 70 years. Since the 1990s, a further five adjuvants have been included in licensed vaccines, but the molecular mechanisms by which these adjuvants work remain only partially understood. However, a revolution in our understanding of the activation of the innate immune system through pattern recognition receptors (PRRs) is improving the mechanistic understanding of adjuvants, and recent conceptual advances highlight the notion that tissue damage, different forms of cell death, and metabolic and nutrient sensors can all modulate the innate immune system to activate adaptive immunity. Furthermore, recent advances in the use of systems biology to probe the molecular networks driving immune response to vaccines ('systems vaccinology') are revealing mechanistic insights and providing a new paradigm for the vaccine discovery and development process. Here, we review the 'known knowns' and 'known unknowns' of adjuvants, discuss these emerging concepts and highlight how our expanding knowledge about innate immunity and systems vaccinology are revitalizing the science and development of novel adjuvants for use in vaccines against COVID-19 and future pandemics.

Citing Articles

Living Bacteria: A New Vehicle for Vaccine Delivery in Cancer Immunotherapy.

Yang M, Zhong P, Wei P Int J Mol Sci. 2025; 26(5).

PMID: 40076679 PMC: 11900161. DOI: 10.3390/ijms26052056.


Harnessing adjuvant-induced epigenetic modulation for enhanced immunity in vaccines and cancer therapy.

Megdiche Y, Salerno-Goncalves R Front Immunol. 2025; 16:1547213.

PMID: 40040700 PMC: 11876029. DOI: 10.3389/fimmu.2025.1547213.


Multidimensional applications of prussian blue-based nanoparticles in cancer immunotherapy.

Zhang J, Wang F, Sun Z, Ye J, Chu H J Nanobiotechnology. 2025; 23(1):161.

PMID: 40033359 PMC: 11874808. DOI: 10.1186/s12951-025-03236-x.


mRNA-LNP vaccine strategies: Effects of adjuvants on non-parenchymal liver cells and tolerance.

Svensson M, Limeres M, Zeyn Y, Gambaro R, Islan G, Berti I Mol Ther Methods Clin Dev. 2025; 33(1):101427.

PMID: 40027262 PMC: 11872076. DOI: 10.1016/j.omtm.2025.101427.


Bioinformatics analysis of the in silico engineered protein vaccine with and without Escherichia coli heat labile enterotoxin adjuvant on the model of Klebsiella pneumoniae.

Ranjbar K, Sarkoohi P, Shahbazi B, Babaei M, Ahmadi K Sci Rep. 2025; 15(1):7321.

PMID: 40025224 PMC: 11873140. DOI: 10.1038/s41598-025-91602-y.


References
1.
De Gregorio E, Tritto E, Rappuoli R . Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol. 2008; 38(8):2068-71. DOI: 10.1002/eji.200838648. View

2.
Beutler B . Inferences, questions and possibilities in Toll-like receptor signalling. Nature. 2004; 430(6996):257-63. DOI: 10.1038/nature02761. View

3.
Kawai T, Akira S . The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010; 11(5):373-84. DOI: 10.1038/ni.1863. View

4.
Medzhitov R . Toll-like receptors and innate immunity. Nat Rev Immunol. 2002; 1(2):135-45. DOI: 10.1038/35100529. View

5.
Coffman R, Sher A, Seder R . Vaccine adjuvants: putting innate immunity to work. Immunity. 2010; 33(4):492-503. PMC: 3420356. DOI: 10.1016/j.immuni.2010.10.002. View